the novel 2 &# 39 ;, 5 &# 39 ;- oligoadenylate analogs of the present invention may be chemically synthesized as follows . a blocked adenosine - 2 &# 39 ;- phosphodiester is prepared by blocking the 6 - amino position with benzoyl , blocking the 5 &# 39 ; position with p - methoxytrityl and optionally blocking the 3 &# 39 ; position with t - butyldimethylsilyl . a blocked nucleoside is prepared by blocking the 2 &# 39 ; and 3 &# 39 ; positions with acetyl , benzoyl or t - butyldimethylsilyl . preparation of suitably blocked adenosine - 2 &# 39 ;- phosphodiesters is carried out by adding the t - butyldimethylsilyl group to the 3 &# 39 ;- o - t - butyldimethylsilyl - isomeric - 3 &# 39 ;- hydroxyl group of n 6 - benzoyl - 5 &# 39 ;- o -( 4 - methoxytrityl ) adenosine by condensing the latter compound with t - butyldimethylsilylchloride using imadazole in pyridine to yield the 3 &# 39 ;- o - t - butyldimethylsilyl derivative . phosphorylation of the derivative is carried out using 2 , 5 - dichlorophenyl - phosphorotriazolide in pyridine to yield a suitably blocked adenosine - 2 &# 39 ;- phosphodiester . this preparation is described in r . charubala , e . uhlmann , and w . pfleiderer , liebigs ann . chem ., 2392 ( 1981 ) and r . charubala , w . pfleiderer , tetrahedron letters 21 , 4077 ( 1980 ), which are specifically incorporated herein by reference . the blocked adenosine - 2 &# 39 ;- phosphodiester is condensed with the blocked nucleoside in the presence of a condensing reagent which causes blocking of the phosphate functions to form a fully protected dinucleosidemonophosphotriester . the resulting fully protected condensate is then detritylated at the terminal 5 &# 39 ; position with a detritylating agent and condensed with a further adenosine - 2 &# 39 ;- phosphodiester , blocked as described above , to form a fully protected 2 &# 39 ;, 5 &# 39 ;- trinucleosidediphosphoditriester , or 2 &# 39 ;, 5 &# 39 ; trimer core . the fully protected trimer core is then treated with appropriate deprotecting reagents to achieve complete deprotection and conversion to 2 &# 39 ;, 5 &# 39 ; trimer core . preparation of the novel 2 ,&# 39 ;, 5 &# 39 ; oligoadenylate analogs is illustrated in the following non - limiting examples . the most preferred analogs of this invention can all be prepared by the method of the following examples as well as by the methods set out in u . s . pat . no . 4 , 464 , 359 which is specifically incorporated herein by reference for that disclosure . the various structurally modified novel trimer core analogs of 2 &# 39 ;, 5 &# 39 ;- adenylate may generally be prepared as follows . one mmole of suitably blocked adenosine - 2 &# 39 ;- phosphodiester having the general formula of reactant ( i ) was prepared from adenosine or cordycepin according to the method of charubala , r ., uhlmann , e ., and pfleiderer , w ., liebigs ann . chem ., 2392 ( 1981 ) and charubala , r ., and pfleiderer , w ., tetrahedron lett . 21 , 4077 ( 1980 ). examples of suitably blocked adenosine - 2 &# 39 ;- phosphodiesters are represented by compounds 1 and 2 , listed in table 1 . ## str8 ## table 1______________________________________ com - poundcompound name no . r r . sup . 1______________________________________pyridinium n . sup . 6benzoyl - 3 &# 39 ;- o . sub .- t - butyldimethylsilyl - 5 &# 39 ;- o - p - methoxytrityladenosine - 2 &# 39 ;- ( 2 - chlorophenyl )- phosphate 1 ## str9 ## pyridinium n . sup . 6benzoyl - 5 &# 39 ;- o - p - methoxytrityl - 3 &# 39 ;- deoxyadenosine - 2 &# 39 ;-( 2 - chlorophenyl )- phosphate 2 h ## str10 ## ______________________________________ reactant ( i ) was combined with a blocked nucleoside having the general formula of reactant ( ii ) below . reactant ( ii ) is exemplified by compounds 3 - 9 listed in table 2 . ## str11 ## table 2__________________________________________________________________________ compoundcompound name no . r r . sup . 1 x__________________________________________________________________________n . sup . 6benzoyl - 2 &# 39 ;, 3 &# 39 ;- di - o . sub .- t - butyldimethylsilyl - adenosine 3 ## str12 ## nn . sup . 6 , 2 &# 39 ;- odibenzoyl - 3 &# 39 ;- 4 h bz ndeoxyadenosinen . sup . 6benzoyl - 2 &# 39 ;- oacetyl - 5 h ac n3 &# 39 ;- deoxyadenosinen . sup . 6 , 2 &# 39 ;- odibenzoyl - 3 &# 39 ;- 6 o - n - c . sub . 5 h . sub . 11 bz no - n - pentyladenosinen . sup . 6 , 2 &# 39 ;- odibenzoyl - 3 &# 39 ;- 7 o - n - c . sub . 7 h . sub . 15 bz no - n - heptyladenosinen . sup . 6benzoyl - 2 &# 39 ;- o . sub .- t - butyldimethylsilyl - 3 &# 39 ;- - p - nitrophenyl - ethoxycarbonylamino - 3 &# 39 ;- deoxyadenosine 8 ## str13 ## ## str14 ## n2 &# 39 ;, 3 &# 39 ;- di - o . sub .- t - butyl - dimethylsilyl - tubercidin 9 ## str15 ## ## str16 ## ch__________________________________________________________________________ ## str17 ## - ## str18 ## - ## str19 ## - ## str20 ## - compounds 3 and 9 are prepared treating n 6 - benzoylated adenosine with monomethoxytrityl chloride in pyridine to yield the 5 &# 39 ;- monomethoxytrityl derivative . the derivative is treated with t - butyldimethylsilylchloride in a mixture of pyridine and methylimidazole to form the n 6 - benzoyl - 2 &# 39 ;, 3 &# 39 ;- di - o - t - butyldimethylsilyl - 5 &# 39 ;- monomethoxytrityl adenosine . the trityl group is removed by acetic acid to produce compound 3 . compound 9 is synthesized analogously , starting with n 6 - benzoylated tubercidin . this method of preparation is as described in charubala et al , liebigs ann . chem . 2392 ( 1981 ). compound 4 is prepared by treating n 6 - benzoylated - 3 &# 39 ;- deoxyadenosine with monomethoxytritylchloride to yield n 6 - benzoyl - 5 &# 39 ;- o - monomethoxytrityl - 3 &# 39 ;- deoxyadenosine ( cordycepin ) which is converted to n 6 - 2 &# 39 ;- o - dibenzoyl - 3 &# 39 ;- deoxyadenosine by benzoylation of the 2 &# 39 ;- hydroxyl group with benzoylchloride followed by detritylation with 80 % acetic acid for 30 minutes . this method of preparation is as described in tetrahedron lett . 21 , 4077 ( 1980 ). compound 5 is prepared by converting n 6 - benzoyladenosine with t - butyldiphenylchlorosilane to the 5 &# 39 ;- silylated nucleoside in pyridine . the 5 &# 39 ;- silylated nucleoside is treated with triethyl orthoacetate followed by boron trifluoride / diethyl ether and sodium iodide in ch 3 cn ( 0 ° c ., 1 hour ) to yield the 3 &# 39 ;- iodoacetyl derivative . the iodoacetyl derivative is converted to compound 5 by treatment with tributyltinhydride in toluene ( 80 ° c ., 1 hour ) and desilylation with ammonium tetrabutyl fluoride in tetrahydrofuran . this method of preparation is as described by engles , j ., in tetrahedron lett . 21 , 4339 ( 1980 ), which is incorporated herein by reference . compounds 6 and 7 are prepared by treating n 6 - benzoyl adenosine with tritylchloride in pyridine and refluxing for 2 hours . n 6 - benzoyl - 5 &# 39 ;- trityladenosine is isolated by extraction with chloroform . the water from the chloroform phase is removed by drying with sodium sulfate . n 6 - benzoyl - 2 &# 39 ;, 5 &# 39 ;- di - o - trityladenosine and n 6 - benzoyl - 3 &# 39 ;, 5 &# 39 ;- di - o - trityladenosine are isolated by preparative silica gel thin layer chromatography in chloroform / ethanol . compounds 6 and 7 are prepared by treating the isolated compounds with n - pentylchloride and n - heptylchloride , respectively , under reflux in a suspension of sodium hydroxide in benzene . the solution is neutralized by refluxing in acetic acid followed by the addition of diethyl ether and water . the reaction products are extracted with chloroform followed by thin layer chromatography with chloroform : methanol ( 4 : 1 ) on silica gel plates . the trityl and benzoyl groups are removed by refluxing in acetic acid for one hour , cooling , extraction with diethyl ether , followed by concentration and cooling to yield crystalline compounds 6 and 7 . this method of preparation is carried out according to blank , h . u ., frahne , d ., myles , a . and pfleiderer , w ., justus liebigs ann . chem . 742 , 34 ( 1970 ), which is incorporated herein by reference . compound 8 was prepared as follows . 1 mmole of 3 &# 39 ;- amino - 3 &# 39 ;- deoxyadenosine was reacted with 1 . 2 mmole of 1 - methyl - 3 - nitrophenylethoxy carboxylimidazolium chloride in dimethylformamide , followed by the addition of hexamethyldisilazane to block the 2 &# 39 ;, 5 &# 39 ; and 6 - amino positions . 1 . 1 mmole of benzoyl chloride in pyridine was added at room temperature to produce blocked n 6 - benzoyl - 2 &# 39 ;, 5 &# 39 ;- disilyladenosine . the reaction mixture was poured into methanol - nh 3 to remove the 2 &# 39 ; and 5 &# 39 ; silyl groups . reaction with mmtr chloride in pyridine yielded the 5 &# 39 ;- mmtr derivative . tert - butyldimethylsilyl chloride in a mixture of pyridine and 1 - methylimidazole was then added to the 5 &# 39 ;- mmtr derivative and 5 &# 39 ;- detritylated as in example 1 to form compound 8 . reactants ( i ) and ( ii ) were combined to produce the intermediate having the general formula of dimer ( iii ) as follows . 0 . 95 mmole of reactant ( ii ) and condensing reagents 2 , 4 , 6 - triisopropylbenzenesulfonyl chloride ( 2 mmole ) and 1 - methylimidazole ( 6 mmole ) were combined and stirred for 1 hr at room temperature . the reaction is stopped by adding 30 ml of aqueous phosphate buffer ph 7 and extracted with 150 ml of chloroform . the chloroform layer was washed twice with 50 ml of water , dried over sodium sulfate about 1 - 2 hr and filtered . the chloroform was evaporated to a small volume and then applied to a silica gel column ( 20 × 2 . 5 cm ) for purification . chromatography was performed first with chloroform and then with chloroform / methanol ( 99 / 1 , v / v ) to elute the fully protected dinucleosidemonophosphotriester product of the general formula of dimer ( iii ). evaporation gave a solid foam of dimer ( iii ) exemplified by compounds 10 - 17 ( table 3 ). ## str21 ## table 3__________________________________________________________________________compound compoundno . r r . sup . 1 r . sup . 2 r . sup . 3 x no . r__________________________________________________________________________10 mmtr obz bz n 18 h11 mmtr ## str22 ## h ac n 19 h12 mmtr ## str23 ## ## str24 ## ## str25 ## ch 20 h13 mmtr ## str26 ## o - n - c . sub . 5 h . sub . 11 bz n 21 h14 mmtr ## str27 ## o - n - c . sub . 7 h . sub . 15 bz n 22 h15 mmtr h obz bz n 23 h16 mmtr h h bz n 24 h17 mmtr ## str28 ## ## str29 ## ## str30 ## n 25 h__________________________________________________________________________ one mmole of the fully protected dimer ( iii ) was stirred at room temperature for 30 minutes in 20 ml of 2 % p - toluenesulfonic acid in dichloromethane / methanol ( 4 / 1 , v / v ) for detritylation . 20 ml of phosphate buffer ph 7 was added and subsequently extracted several times with 200 ml of dichloromethane . the organic phase was washed with water , dried over sodium sulfate , evaporated to a small volume and then applied to a silica gel column ( 20 × 2 . 5 cm ) for purification . elution was performed with chloroform ( 400 ml ) followed by chloroform / methanol ( 98 / 2 , v / v ). evaporation of the main fraction gave a 80 - 90 % yield of the detritylated dinucleosidemonophosphotriester ( dimer ( iii )), exemplified by compounds 18 - 25 , ( table 3 ). the fully protected 2 &# 39 ;, 5 &# 39 ;- trinucleosidediphosphoditriester , having the general formula of trimer ( iv ) and exemplified by compounds 26 - 34 ( table 4 , below ), was prepared from the 5 &# 39 ;- detritylated dimer ( iii ) as follows . ## str31 ## table 4__________________________________________________________________________compoundno . r r . sup . 1 r . sup . 2 r . sup . 3 x__________________________________________________________________________26 h obz bz n27 h ## str32 ## h ac n28 ## str33 ## ## str34 ## ## str35 ## ## str36 ## ch29 ## str37 ## ## str38 ## o - n - c . sub . 5 h . sub . 11 bz n30 ## str39 ## ## str40 ## o - n - c . sub . 7 h . sub . 15 bz n31 ## str41 ## ## str42 ## obz bz n32 h h obz bz n33 ## str43 ## h h bz n34 ## str44 ## ## str45 ## ## str46 ## ## str47 ## n__________________________________________________________________________ 1 . 05 mmole of the starting adenosine - 2 &# 39 ;- phosphodiester ( reactant ( i )), was condensed with 1 mmole of the 5 &# 39 ;- detritylated dimer ( iii ) ( compounds 18 - 25 ) in 10 ml of absolute pyridine using 3 mmole of 2 , 4 , 6 - triisopropylbenzenesulfonyl chloride and 9 mmole of 1 - methylimidazole as condensing agents . work - up was performed after 2 hr in the manner as described above . quenching with phosphate buffer , followed by extraction with dichloromethane and silica gel chromatography in chloroform and chloroform / methanol ( 99 / 1 to 98 / 2 , v / v ) yielded 70 - 90 % of fully protected trimer ( iv ) ( compounds 26 - 34 ), as a chromatographically pure amorphous powder . the fully protected 2 &# 39 ;, 5 &# 39 ;- trinucleosidediphosphoditriester , trimer ( iv ), was deprotected to trimer core ( v ) as follows . 0 . 01 mole of trimer ( iv ) was treated with a solution of 0 . 073 g p - nitrobenzaldeoxime and 0 . 07 g tetramethylguanidine in 2 ml of dioxane water ( 1 / 1 , v / v ) for 16 hrs at room temperature to deblock the o - chlorophenyl group . after evaporation to dryness and coevaporation four times with water , 20 ml of concentrated ammonium hydroxide was added and the solution stirred for 2 days at room temperature to deprotect the acyl groups . the solution was then evaporated again , and the residue was dissolved in 25 ml of water and washed for times with 10 ml of chloroform each time . the water layer was evaporated to dryness and coevaporaed ten times with 10 ml absolute pyridine each time . the residue was then treated with 2 ml of an 0 . 5m solution of anhydrous tetrabutylammonium fluoride in absolute pyridine for 16 hrs to remove the t - butyldimethylsilyl groups . after evaporation , treatment of the residue with 5 ml of 80 % acetic acid for 6 hrs at room temperature lead to cleavage of the p - methoxytrityl group . the solution was again evaporated , the residue dissolved in 15 ml of water , and extracted four times with 5 ml of chloroform each time . the aqueous layer was evaporated and then coevaporated several times with water until the smell of acetic acid disappeared . the residue was dissolved in 10 ml of water and applied to a deae - sephadex a - 25 column ( 60 × 1 cm ) for ion - exchange chromatography with a gradient of 0 . 001 - 0 . 5m triethylammonium bicarbonate . the main fraction was evaporated , then coevaporated several times with water . trimer core ( v ), a fully deprotected 2 &# 39 ;, 5 &# 39 ;- trinucleosidediphosphate , was isolated by lyophilization of the aqueous solution to give 70 - 90 % of an amorphous solid . trimer core ( v ) is exemplified by compounds 35 - 45 ( table 5 ). ## str48 ## table 5__________________________________________________________________________compound compoundname no . r r . sup . 1 r . sup . 2 r . sup . 3 x__________________________________________________________________________2 &# 39 ;, 5 &# 39 ;- a -- a -- c 35 h oh oh h n2 &# 39 ;, 5 &# 39 ;- c -- a -- c 36 h h oh h n2 &# 39 ;, 5 &# 39 ;- a -- a -- tu 37 h oh oh oh ch2 &# 39 ;, 5 &# 39 ;- a -- a -- a -- 38 h oh oh o -- - n - c . sub . 5 h . sub . 11 n3 &# 39 ;- o -- pentyl2 &# 39 ;, 5 &# 39 ;- a -- a -- a -- 39 h oh oh o -- - n - c . sub . 7 h . sub . 15 n3 &# 39 ;- o -- heptyl2 &# 39 ;, 5 &# 39 ;- a . sub . ( si ) -- 40 h osi ++ osi ++ oh na . sub . ( si ) -- a2 &# 39 ;, 5 &# 39 ;- c -- c -- a 41 h h h oh n2 &# 39 ;, 5 &# 39 ;- a -- c -- c 42 h oh h h n2 &# 39 ;, 5 &# 39 ;- a -- a -- 43 h oh oh nh . sub . 2 n3 &# 39 ;- amino2 &# 39 ;, 5 &# 39 ;- trityl -- a . sub . 3 44 mmtr oh oh oh n2 &# 39 ;, 5 &# 39 ;- trityl -- c . sub . 3 45 mmtr h h h n2 &# 39 ;, 5 &# 39 ;- c -- c -- c -- 46 h . sub . 2 o . sub . 3 p h h h n5 &# 39 ;- monophosphate__________________________________________________________________________ 0 . 01 mmole of n 6 - benzoyl - 3 &# 39 ;- o - t - butyldimethylsilyl - 5 &# 39 ;- o - p - methoxytrityladenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 - benzoyl - 3 &# 39 ;- o - t - butyldimethylsilyladenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 , 2 &# 39 ;- o , 3 &# 39 ;- o - tribenzoyladenosine ( compound 31 , table 4 ) was treated according to the procedure of example 1 , except that the deprotection step of treatment with tetrabutylammoniumfluoride was omitted , in order to produce 2 &# 39 ;, 5 &# 39 ;- a . sub . ( si ) - a . sub . ( si ) - a ( compound 40 , table 5 ). 0 . 01 mmole of n 6 - benzoyl - 3 &# 39 ;- o - t - butyldimethylsilyl - 5 &# 39 ;- o - p - methoxytrityladenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 - benzoyl - 3 &# 39 ;- o - t - butyldimethylsilyladenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 - benzoyl - 2 &# 39 ;- o - t - butyldimethylsilyl - 3 &# 39 ;- p - nitrophenylethoxycarbonylamino - 3 &# 39 ;- deoxyadenosine ( compound 34 , table 4 ) was treated according to the deprotection procedure of example 1 wherein the p - nitrophenylethoxycarbonyl group was cleaved simultaneously with the silyl groups by tetrabutylammonium fluoride in a β - elimination process . subsequent decarboxylation yields 2 &# 39 ;, 5 &# 39 ;- a - a - 3 &# 39 ;- amino ( compound 43 , table 5 ). 0 . 01 mmole of n 6 - benzoyl - 3 &# 39 ;- o - t - butyldimethylsilyl - 5 &# 39 ;- o - p - methoxytrityladenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 - benzoyl - 3 &# 39 ;- o - t - butyldimethylsilyladenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 , n . sup . 6 - 2 &# 39 ;- 0 , 3 &# 39 ;- o - tetrabenzoyladenosine prepared according to the method of charubala , r ., uhlmann , e ., and pfleiderer , w ., liebigs ann . chem ., 2392 ( 1981 ) was treated according to the deprotection procedure of example 1 except that the last step of acetic acid treatment was omitted . the product , 2 &# 39 ;, 5 &# 39 ;- trityl - a 3 ( compound 44 , table 5 ) was isolated , purified by deae - sephadex a - 25 chromatography , and lyophilized to form the amorphous pure compound 44 as a powder in 85 % yield . 0 . 01 mmole of n 6 - benzoyl - 5 &# 39 ;- o - p - methoxytrityl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n . sup . - benzoyl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 , n 6 , 2 &# 39 ;- o - tribenzoyl - 3 &# 39 ;- deoxyadenosine prepared according to the method of charubala , r ., and pfleiderer , w ., tetrahedron lett . 21 , 4077 ( 1980 ) was treated according to the deprotection procedure of example 1 except that the steps of treatment with tetrabutylammonium fluoride and acetic acid were omitted . the product , 2 &# 39 ;, 5 &# 39 ;- trityl - c 3 ( compound 45 , table 5 ) was isolated , purified by deae - sephadex a - 25 chromatography and lyophilized to form the amorphous pure compound . the 5 &# 39 ;- monophosphates of the trimer core molecules of the present invention may be prepared from the fully blocked 2 &# 39 ;, 5 &# 39 ;- trinucleosidediphosphoditriester by detritylation as in example 1 followed by reaction with di - p - nitrophenylethylphosphoryl chloride . extraction , chromatography and deblocking according to example 1 results in isolation of the 5 &# 39 ;- monophosphate trimers . the preparation is exemplified in the method of example 6 . 0 . 1 mmole of n 6 - benzoyl - 5 &# 39 ;- o - p - methoxytrityl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n . sup . 6 - benzoyl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 , n 6 , 2 &# 39 ;- o - tribenzoyl - 3 &# 39 ;- deoxyadenosine is prepared from 3 &# 39 ;- deoxyadenosine by benzoylation , 5 &# 39 ;- tosylation , and 2 &# 39 ;- phorsphorylation , with formation of the dinucleoside phosphotriester , n 4 - benzoyl ( 2 - o - chlorophenylphosphoryl - 5 ) 3 &# 39 ;- deoxyadenosine , by treatment of the reaction products n 6 - benzoyl ( 2 - triethylammonium - o - chlorophenylphosphoryl - 5 )- 5 &# 39 ;- tosyl - 3 &# 39 ;- deoxyadenosine and 2 &# 39 ;- cyanoethylphosphoryl - o - chlorophenyl - 3 &# 39 ;- deoxyadenosine with triisopropylbenzenesulfonyl - nitro - 1 , 2 , 4 - triazolide . the fully blocked dimer thus formed is condensed with n 6 , 2 &# 39 ;- o - dibenzoyl - 3 &# 39 ;- deoxyadenosine to form the trimer . 0 . 1 mm of this trimer prepared according to the method of charubala , r ., and pfleiderer , w ., tetrahedron lett . 21 , 4077 ( 1980 ) was treated with 2 ml of a solution of 2 % p - toluenesulfonic acid in dichloromethane / methanol ( 7 / 3 , v / v ) for 30 minutes at room temperature to remove the p - methoxytrityl group . purification by silica gel chromatography on a preparative plate with chloroform / methanol ( 95 / 5 , v / v ) gave a 90 % yield of the 5 &# 39 ;- deprotected analog . this product was dissolved in 1 l of absolute pyridine and treated with 0 . 27 mmole of di - p - nitrophenylethylphosphoryl chloride as described by himmelsbach , f ., and pfleiderer , w ., tetrahedron lett . 23 , 4793 ( 1982 ) for 1 hr at room temperature . after dilution with 15 ml of chloroform , the reaction mixture was extracted three times with phosphate buffer ph 7 . the organic layer was dried over sodium sulfate , filtered , evaporated and coevaporated three times with 10 ml of toluene each time . the residue was purified by silica gel chromatography on preparative plates in chloroform / methanol ( 9 / 1 , v / v ) to yield 81 % of 5 &# 39 ;- o - di - p - nitrophenylethylphosphoryl - n 6 - benzoyl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 - benzoyl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 , n 6 , 2 &# 39 ;- o - tribenzoyl - 3 &# 39 ;- deoxyadenosine in the form of an amorphous solid . 0 . 01 mmole of the latter material was treated with p - nitrobenzaldoximate according to the deprotection procedure of example 1 to remove o - chlorophenyl blocking groups . after evaporation to dryness and several coevaporations with absolute pyridine , the deprotected product was dissolved in 10 ml of a 0 . 5m solution of diazabicyclo [ 4 . 3 . 0 ] undecene in absolute pyridine and stirred for 36 hours at room temperature to cleave the p - nitrophenylethyl group by β - elimination . the solution was again evaporated and then treated with 20 ml of concentrated ammonium hydroxide for 24 hours at room temperature . purification and isolation of the trimer core 5 &# 39 ;- monophosphate ( compound 46 , table 5 ) was achieved by deae - sephadex chromatography and lyophilization of the main fraction . the tetramer core molecules of the present invention may be prepared by following the method of examples 7 or 8 . 0 . 5 mmole of fully - protected compound 47 having the formula ( vi ) and 0 . 4 mmole of n 6 - benzoyl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - b 5 &# 39 ;) n 6 , 2 &# 39 ;- o - dibenzoyl - 3 &# 39 ;- deoxyadenosine ( compound 24 , table 3 ) were dissolved in 5 ml of absolute pyridine . ## str49 ## following addition of 1 mmole of 2 , 4 , 6 - triisopropylbenzenesulfonyl chloride and 3 mmole of 1 - methylimidazone , the mixture was stirred for 2 hrs at room temperature . the solution was diluted with 400 ml of chloroform , washed twice with 400 ml of water , then the organic layer was dried over sodium sulfate , filtered and evaporated to dryness . the residue was coevaporated twice with 50 ml of toluene . purification was achieved by chromatography on a silica gel column ( 20 × 2 . 5 cm ) first with chloroform and then with a gradient of chloroform / methanol of 99 / 1 to 98 / 2 ( v / v ). on evaporation , the main fraction gave compound 48 ( table 6 ) as a solid form in 80 % yield . compound 48 is a fully blocked 2 &# 39 ;, 5 &# 39 ;- tetranucleosidetriphosphotritriester according to the general formula of tetramer core ( vii ), below . deprotection of the blocking groups was performed by the procedure of example 1 to yield 2 &# 39 ;, 5 &# 39 ;- a -- a -- c -- c ( compound 49 , table 6 ). deae - sephadex chromatography , evaporation and lyophilization resulted in an amorphous solid in 80 % yield . ## str50 ## table 6______________________________________compoundno . r r . sup . 1 r . sup . 2 r . sup . 3______________________________________48 bz mmtr ## str51 ## 49 h h h h______________________________________ 0 . 1 mmole of n 6 - benzoyl - 5 &# 39 ;- o - p - methoxytrityl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n . sup . - benzoyl - 3 &# 39 ;- deoxyadenylyl ( 2 &# 39 ;- o - chlorophenyl - 5 &# 39 ;) n 6 , n 6 , 2 &# 39 ;- o - tribenzoyl - 3 - deoxyadenosine ( compound 50 , table 7 ), a fully - blocked 2 &# 39 ;, 5 &# 39 ;- trinucleosidediphosphoditriester according to the general formula of reactant ( viii ), ## str52 ## table 7______________________________________compound no . r______________________________________50 mmtr51 h______________________________________ was treated with 2 ml of a 2 % solution fo p - toluenesulfonic acid in dichloromethane / methanol ( 4 / 1 , v / v ) for 30 minutes at room temperature . the reaction was stopped by adding 20 ml of phosphite buffer ph 7 . the solution was extracted several times with 200 ml of chloroform . the organic layer was washed with water , dried over sodium sulfate , filtered and evaporated to a small volume for purification on preparative silica gel plates in chloroform / methanol ( 95 / 5 , v / v ). the main band was eluted by chloroform / methanol ( 4 / 1 , v / v ) to give the 5 &# 39 ;- detritylated compound 51 ( table 7 ) upon evaporation in 80 % yield . 0 . 05 mmole of compound 51 ( table 7 ) was then condensed with 0 . 1 mmole of pyridinium n 6 - benzoyl - 5 &# 39 ;- o - p - methoxytrityl - 3 &# 39 ;- deoxyadenosine - 2 &# 39 ;-( 2 - o - chlorophenyl ) phosphate ( compound 2 , table 1 ) in 0 . 6 ml of absolute pyridine in the presence of 0 . 2 mmole of 2 , 4 , 6 - triisopropylbenzenesulfonyl chloride and 0 . 6 mmole of 1 - methylimidazole for 2 hrs at room temperature . the solution was diluted with 100 ml of chloroform , washed twice with water , dried over sodium sulfate and evaporated to a small volume for separation on preparative silica gel plates in chloroform / methanol ( 95 / 5 , v / v ). the main band was eluted with chloroform to give the fully - protected 2 &# 39 ;, 5 &# 39 ;- tetranucleosidetriphosphotritriester compound 52 ( table 8 , below ) as an amorphous solid upon evaporation in 84 % yield . the blocking groups of compound 52 were removed according to the procedure of example 1 , followed by deae - sephadex chromatography and lyophilization . tetramer core 2 &# 39 ;, 5 &# 39 ;- c -- c -- c -- c ( compound 53 , table 8 ) resulted as an amorphous solid in 70 % yield . the structure of compound 53 is according to the general formul of tetramer core ( ix ). the 5 &# 39 ;- o - monophosphates of the tetramer core molecules of the present invention may be prepared from the fully blocked 2 &# 39 ;, 5 &# 39 ;- tetranucleosidetriphosphotritriester by 5 &# 39 ;- detritylation as in example 1 followed by reaction with di - p - nitrophenylethylphosphoryl chloride . extraction , chromatography and deblocking according to example 1 results in isolation of the 5 &# 39 ;- o - monophosphate tetramers . the preparation is exemplified in example 6 . ## str53 ## the 5 &# 39 ;- diphosphate and 5 &# 39 ;- triphosphate of the trimer and tetramer core molecules of the present invention may be prepared by adding 0 . 5 mm of tributylammonium pyrophosphate dissolved in 5 ml of dimethylformamide to 0 . 1 mm of monophosphorylated core as the anhydrous tributylammonium salt in 1 ml of dimethylformamide and 0 . 5 mm of 1 , 1 &# 39 ;- carbonyldiimidazole . after 20 hours at room temperature , the reactants are treated with 5 ml of methanol , evaporated to dryness and chromatographed on a 2 × 20 cm deae cellulose column . the 5 &# 39 ;- di and triphosphates are isolated following a linear gradient ( 0 - 0 . 4m in 3 l at ph 7 . 5 ) of triethylammoniumbicarbonate . this is the method of hoard , d . e ., and ott , d . g ., j . amer . chem . soc . 87 , 1785 - 1788 ( 1965 ), which is incorporated herein by reference . the 5 &# 39 ;- diphosphates and 5 &# 39 ;- triphosphates may then be purified by deae - sephadex a25 and sephadex the 2 &# 39 ;, 5 &# 39 ;- oligoadenylate analogs , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c -- c , 2 &# 39 ;, 5 &# 39 ;- i 3 , 2 &# 39 ;, 5 &# 39 ;- a -- a - ara - a , 2 &# 39 ;, 5 &# 39 ;- a -- a -- tu , and 2 &# 39 ;, 5 &# 39 ;- xylo - a 3 , were all potent inhibitors of tmv replication in n . glutinosa leaves . 2 &# 39 ;, 5 &# 39 ;- c -- c -- c -- c , 2 &# 39 ;, 5 &# 39 ;- a -- a - ara - a , and 2 &# 39 ;, 5 &# 39 ;- a -- a -- tu were more potent inhibitors than the naturally occurring 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core . the trimer and tetramer core xylo - a 3 and xylo - a 4 are synthesized by treating n 6 - 3 &# 39 ;- o - dibenzoylated xylofuranose with t - butyldimethylsilylchloride to yield the silylated derivative of n 6 - 3 &# 39 ;- o - dibenzylated xylofuranose which is debenzoylated with sodium methoxide to form the 2 &# 39 ;- silyl derivative . the primary hydroxyl of the 2 &# 39 ;- silyl derivative is protected with a monomethoxytrityl group and the resulting 5 &# 39 ;- tritylated - 2 &# 39 ;- silyl derivative is reacted with an equimolar equivalent of benzoic anhydride dissolved in pyridine in the presence of 4 - dimethylaminopyridine to yield the n 6 and 3 - o - benzoylated - 5 &# 39 ;- tritylated - 2 &# 39 ;- silylated derivative . removal of the t - butyldimethylsilyl group with tetrabutylammonium fluoride gives the n 6 and 3 - o - dibenzoylated - 5 &# 39 ;- tritylated derivative which is successively benzoylated and detritylated to produce n 6 , 2 &# 39 ;, 3 &# 39 ;- o - tribenzoylxyloadenosine . the previous n 6 and 3 - o - dibenzoylated - 5 &# 39 ;- tritylated derivative is also reacted with an excess of o - chlorophenylphosphoro - di -( 1 , 2 , 4 - triazolide ) in an acetonitrile - pyridine mixture followed by a reaction with aqueous triethylamine to form the 2 &# 39 ;- phosphotriester . the phosphotriester is condensed with n 6 , 2 &# 39 ;, 3 &# 39 ;- o - tribenzoylxyloadenosine in the presence of 1 - mesitylenesulfonyl - 3 - nitro - 1 , 2 , 4 - triazole to yield the fully protected dinucleosidephosphotriester which is detritylated by treatment with p - toluenesulfonic acid in a mixture of chloroform and methanol ( 4 : 3 ). a final condensation between the detritylated product and the phosphotriester and purification by silica gel chromatography yields the fully protected trinucleosidediphosphotriester ( blocked trimer core ). the fully deblocked trimer core is obtained by treatment of the blocked trimer core with tetramethylguanidinium - syn - 4 - nitrobenzaldoximate , aqueous ammonia , and 80 % acetic acid . preparation of the trimer core 2 &# 39 ;, 5 &# 39 ;- xylo - a 3 and tetramer core 2 &# 39 ;, 5 &# 39 ;- xylo - a 4 is reported in grosselin , g . and imbach , j .- l ., tetrahedron lett . 22 , 4699 ( 1981 ), which is incorporated herein by reference . when the 3 &# 39 ;- hydroxyl function of the adenylate residues of 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core was replaced with a 3 &# 39 ;- hydrogen atom , the modified analog , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , was the most potent inhibitor of tmv replication . this molecule completely inhibited tmv replication for 96 hours , compared to the naturally occurring 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core which inhibited tmv replication for only 48 hours . 2 &# 39 ;, 5 &# 39 ;- c -- c -- c also inhibited hsv - 1 replication , ebv - induced morphological transformation of lymphocytes and ascites tumor growth . it inhibited solid tumor growth . 2 &# 39 ;, 5 &# 39 ; trimer cores containing adenylate and cordycepin residues with the general formulae , 2 &# 39 ;, 5 &# 39 ;- a -- a -- c , 2 &# 39 ;, 5 &# 39 ;- a -- c -- c , 2 &# 39 ;, 5 &# 39 ;- c -- c -- a , and 2 &# 39 ;, 5 &# 39 ;- c -- a -- c , were synthesized as described in the above examples . 2 &# 39 ;, 5 &# 39 ;- a -- a -- c was as good as 2 &# 39 ;, 5 &# 39 ;- c -- c -- c in inhibiting ascites tumor growth in animals . however , 2 &# 39 ;, 5 &# 39 ;- a -- c -- c was without effect . thus , a change in a single adenylate residue may significantly impact on the spectrum of biological activity . when the 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core was modified at the 2 &# 39 ;- terminus , i . e ., 2 &# 39 ;, 5 &# 39 ;- a -- a -- tu or 2 &# 39 ;, 5 &# 39 ;- a -- a - ara - a , there was excellent inhibition of tmv replication . these 2 &# 39 ;- terminally modified molecules are also extremely effective in preventing ebv - induced morphological transformation . the analogs 2 &# 39 ;, 5 &# 39 ;- a -- a - 3 &# 39 ;- amino , 2 &# 39 ;, 5 &# 39 ;- a -- a -- a - 3 &# 39 ;- o - pentyl and 2 &# 39 ;, 5 &# 39 ;- a -- a -- a - 3 &# 39 ;- o - heptyl are believed to inhibit vaccinia virus infected cells . the 5 &# 39 ;- terminus of the 2 &# 39 ;, 5 &# 39 ;- adenylate and 2 &# 39 ;, 5 &# 39 ;- cordycepin cores was modified by the replacement of the 5 &# 39 ;- hydrogen on the hydroxyl with a p - methoxytrityl group . the 2 &# 39 ;, 5 &# 39 ;- trityl - a 3 analog is as potent an inhibitor of ebv - induced morphological transformation as the cordycepin core ( see table 13 ). when the 2 &# 39 ;, 5 &# 39 ;- a 3 molecule was modified at the 2 &# 39 ;, 5 &# 39 ;- adenylyl residues to form 2 &# 39 ;, 5 &# 39 ;- a . sub . ( si ) - a . sub . ( si ) - a , there was a marked inhibition of ebv - induced transformation of infected lymphocytes . structural modifications of the 2 &# 39 ;, 5 &# 39 ;- oligoadenylate molecule at the 2 &# 39 ;- terminal nucleoside , aglycon and / or ribosyl moiety have provided molecules that are potent inhibitors of tumor growth in mammals and virus replication in plants and mammals . these synthetic molecules are biologically more active and metabolically more stable than the naturally occurring 2 &# 39 ;, 5 &# 39 ;- oligoadenylate molecule . moreover , they show no cytotoxicity . the antiviral activity of the compounds of the present invention is demonstrated by the following experiments in which any of the most preferred compounds of the invention and their 5 &# 39 ;- mono -, di -, and triphosphate counterparts may be substituted for any of the analogs in the following experiments with the efficacy disclosed for such compounds in the specification . the effectiveness of 2 &# 39 ;, 5 &# 39 ;- oligoadenylate analogs of the present invention against plant virus is demonstrated using tmv - infected leaves of n . glutinosa and n . tabacum . the growth of n . glutinosa , n . tabacum var . &# 34 ; samsun , n . tabacum cv . samsun nn , and preparation and inoculation of protoplasts was carried out according to the method as described by loebenstein , g ., and gera , a ., virology 114 , 132 - 139 ( 1981 ) and loebenstein , g ., gera . a ., barnett , a ., shabtai , s ., and cohen , j ., virology 100 , 110 - 115 ( 1980 ). to evaluate the effect of 2 &# 39 ;, 5 &# 39 ; oligomers on tmv replication , various concentrations of oligomer were added to 10 ml of protoplast suspension ( 1 × 10 5 cells / ml ) at various times after inoculation with tmv . protoplasts were incubated at 25 ° c . under continuous illumination of about 1500 lx . at various times protoplasts were collected by centrifugation and homogenized . the homogenate was inoculated onto half - leaves of n . glutinosa plants and compared to a standard solution of purified tmv on the opposite half - leaves . lesion counts were adjusted to 10 6 live protoplasts and calibrated . control protoplasts ( no nucleotides added ) were assayed simultaneously . assays for antiviral activity on tmv - infected tobacco leaf discs were performed by enzyme - linked immunosorbent assay ( elisa ). the ability of the 2 &# 39 ;, 5 &# 39 ;- adenylate analog cores , nucleosides , and nucleotides to inhibit tmv replication in the intact plant was determined by infectivity tests as follows . solutions containing 5 μg / ml tmv , 0 . 1 g carborundum ( 200 mesh ), and 2 &# 39 ;, 5 &# 39 ;- adenylate analog cores , nucleosides , or nucleotides were applied onto half - leaves of n . glutinosa ( loebenstein , g ., and gera , a ., virology 114 , 132 - 139 ( 1981 ). the remaining half - leaves were controls ( inoculated with a solution containing no active compound ). the infection was allowed to proceed 48 hr under continuous illumination of about 1500 lx at which time local virus lesions appeared . inhibition of tmv replication was calculated as the percent of local lesions produced in 2 &# 39 ;, 5 &# 39 ;- oligoadenylate analog - treated half - leaves compared to control half - leaves . inhibition of tmv replication by 2 &# 39 ;, 5 &# 39 ;- adenylate analog cores in tobacco protoplasts and leaf discs the effect of 2 &# 39 ;, 5 &# 39 ;- oligomer cores on the inhibition of tmv replication in protoplasts was measured . at 1 × 10 - 8 m , 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core in protoplast medium inhibited tmv replication 53 % after 72 hr ( table 9 ). the inhibition of virus replication by the 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core was dose dependent . 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core and 2 &# 39 ;, 5 &# 39 ;- cordycepin trimer core inhibited tmv replication 93 % and 96 %, respectively , at 1 × 10 - 7 m . 3 &# 39 ;, 5 &# 39 ;- adenylate trimer core was of similar potency to amp . the 2 &# 39 ;, 5 &# 39 ;- inosine trimer core caused about 50 % inhibition of tmv replication at 1 × 10 - 7 m . adenosine , amp , cordycepin , 3 &# 39 ; damp , and inosine ( possible degradation products ) were less inhibitory . a maximum antiviral effect was obtained when the 2 &# 39 ;, 5 &# 39 ;- adenylate analog cores were added earlier than 5 hr after inoculation with tmv ( table 10 ). the antiviral effect was decreased when 2 &# 39 ;, 5 &# 39 ;- adenylate analog cores were added 5 and 12 hr after infection . table 9__________________________________________________________________________the inhibition of tmv replication in tobacco protoplastsby 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core and analogs . sup . a inhibition . sup . bnucleotide concentration after 24 hr after 48 hr after 72 hradded ( m ) (%) (%) (%) __________________________________________________________________________no addition -- 0 0 02 &# 39 ;, 5 &# 39 ;- a . sub . 3 1 × 10 . sup .- 8 48 ( p & lt ; 0 . 01 ) 41 ( p & lt ; 0 . 01 ) 53 . 0 ( p & lt ; 0 . 01 ) 1 × 10 . sup .- 7 92 ( p & lt ; 0 . 01 ) 93 ( p & lt ; 0 . 01 ) 92 ( p & lt ; 0 . 01 ) 3 &# 39 ;, 5 &# 39 ;- a . sub . 3 1 × 10 . sup .- 7 27 ( p & lt ; 0 . 01 ) 38 ( p & lt ; 0 . 01 ) ndadenosine 1 × 10 . sup .- 7 14 ( p & lt ; 0 . 01 ) 0 ndamp 1 × 10 . sup .- 7 22 ( p & lt ; 0 . 01 ) 33 ( p & lt ; 0 . 01 ) nd2 &# 39 ;, 5 &# 39 ;- c -- c -- c 1 × 10 . sup .- 7 95 ( p & lt ; 0 . 01 ) 96 ( p & lt ; 0 . 01 ) ndcordycepin 1 × 10 . sup .- 7 nd . sup . c 21 ( p & lt ; 0 . 01 ) 32 ( p & lt ; 0 . 01 ) 3 &# 39 ; damp 1 × 10 . sup .- 7 nd 41 ( p & lt ; 0 . 01 ) 45 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- i . sub . 3 1 × 10 . sup .- 7 53 ( p & lt ; 0 . 01 ) 54 ( p & lt ; 0 . 01 ) ndinosine 1 × 10 . sup .- 7 nd 22 ( p & lt ; 0 . 01 ) 25 ( p & lt ; 0 . 01 ) __________________________________________________________________________ . sup . a 2 &# 39 ;, 5 or 3 &# 39 ;, 5adenylate trimer cores , nucleosides and nucleotides were added to the tmvinfected protoplasts within 3 hr of infection . . sup . b average of four experiments . inhibition of tmv replication observe by the 2 &# 39 ;, 5adenylate cores , nucleosides and nucleotides was calculated as the percent of local lesions produced in n . glutinosa treated by homogenates of protoplasts compared to nontreated protoplasts . . sup . c not determined . table 10______________________________________inhibition of tmv replication in tobacco protoplaststreated with 2 &# 39 ;, 5 &# 39 ;- adenylate trimer core and analogat various times after infection time of addition ( hr after inoculation ) inhibition . sup . bcompound after 0 hr after 5 hr after 12 hradded . sup . a (%) (%) (%) ______________________________________no addition 0 0 02 &# 39 ;, 5 &# 39 ;- a . sub . 3 78 ( p & lt ; 0 . 01 ) 59 ( p & lt ; 0 . 01 ) 44 ( p & lt ; 0 . 01 ) 3 &# 39 ;, 5 &# 39 ;- a . sub . 3 31 ( p & lt ; 0 . 01 ) 24 ( p & lt ; 0 . 01 ) 23 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- c -- c -- c 78 ( p & lt ; 0 . 01 ) 66 ( p & lt ; 0 . 01 ) 53 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- i . sub . 3 60 ( p & lt ; 0 . 01 ) 50 ( p & lt ; 0 . 01 ) 37 ( p & lt ; 0 . 01 ) ______________________________________ . sup . a final concentration of 2 &# 39 ;, 5oligoadenylate trimer cores in protoplast medium was 5 × 10 . sup .- 8 m . . sup . b inhibition of tmv replication was determined 48 hr after infection and calculated as in table 9 footnote b . inhibition of tmv replication by 2 &# 39 ;, 5 &# 39 ;- adenylate analog cores with increasing time the kinetics of the inhibition of tmv - replication by the 2 &# 39 ;, 5 &# 39 ;- a 3 core and 2 &# 39 ;, 5 &# 39 ;- c -- c -- c in infected leaf discs was determined as follows . leaves were mechanically inoculated with purified virus ( 5 μg / ml in 0 . 1m sodium phosphate buffer , ph 7 . 6 , containing 0 . 1 g / ml of carborundum ). leaf discs ( 6 . 5 mm diameter ) were punched out of the inoculated leaves and placed in a beaker containing 0 . 01m sodium phosphate , ph 7 . 6 . groups of 20 discs were selected at random from this common pool and placed into separate petri dishes , each containing 20 ml of sodium phosphate buffer . buffer was aspirated from the dishes after 1 hour . the tmv - inoculated tobacco leaf discs were treated for one hr with 200 nm 2 &# 39 ;, 5 &# 39 ;- a 3 or 200 nm 2 &# 39 ;, 5 &# 39 ;- c -- c -- c . the discs were washed and the infection was allowed to proceed at room temperature under constant illumination . the discs were then homogenized and the tmv content was determined by elisa . virus protection was inhibited for 48 hr by 2 &# 39 ;, 5 &# 39 ;- a 3 core , but the inhibitory effect gradually diminished after 48 hr . however , tmv inhibition by 2 &# 39 ; , 5 &# 39 ;- c -- c -- c was noted for 96 hr ( see figure ). the extended inhibitory activity of the 2 &# 39 ;, 5 &# 39 ;- c -- c -- c compared to the naturally occurring adenylate core may be due to increased stability of the analog , an effect of increased uptake , or a different inhibitory mechanism . effect of 2 &# 39 ;, 5 &# 39 ;- a 3 and its analogs on tmv replication in intact plants 2 &# 39 ;, 5 &# 39 ;- a 3 , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , 2 &# 39 ;, 5 &# 39 ;- xylo - a 3 , 2 &# 39 ;, 5 &# 39 ;- i 3 , 2 &# 39 ;, 5 &# 39 ;- a -- a - ara - a , and 2 &# 39 ;, 5 &# 39 ;- a -- a -- tu were potent inhibitors of tmv replication when applied to leaves of n . glutinosa at 1 × 10 - 6 m in the tmv - infecting solution . the aforementioned trimer cores inhibited the formation of local lesions following tmv infection by 89 - 99 % ( table 11 ). the nucleosides and nucleotides were not antivirally active , or they exhibited negligible activity at 1 × 10 - 6 m . 2 &# 39 ;, 5 &# 39 ;- a 3 , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , and 2 &# 39 ;, 5 &# 39 ;- i 3 inhibited tmv replication in a dose - dependent manner . 2 &# 39 ;, 5 &# 39 ;- i 3 was not as good ( 68 % inhibition at 1 × 10 - 6 m ) as 2 &# 39 ;, 5 &# 39 ;- a 3 and 2 &# 39 ;, 5 &# 39 ;- c -- c -- c ( 91 % and 93 % inhibition at 1 × 10 - 6 m , respectively ) ( table 12 ). non - infected plants were treated with 1 × 10 - 6 m of 2 &# 39 ;, 5 &# 39 ;- a 3 , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , 2 &# 39 ;, 5 &# 39 ;- a -- a - ara - a , and 2 &# 39 ;, 5 &# 39 ;- a -- a -- tu . no toxicity ( chlorosis or necrosis ) was observed during the two week period tested . table 11______________________________________effect of 2 &# 39 ;, 5 &# 39 ;- a . sub . 3 , 2 &# 39 ;, 5 &# 39 ;- adenylate coreanalogs , nucleosides and nucleotides on tmvreplication in n . glutinosa leaves inhibition . sup . baddition . sup . a % ______________________________________no addition 02 &# 39 ;, 5 &# 39 ;- a . sub . 3 93 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- c -- c -- c 99 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- i . sub . 3 92 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- a -- a -- ara - a 94 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- a -- a -- tu 95 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- xylo -- a . sub . 3 89 ( p & lt ; 0 . 01 ) amp 10cordycepin monophosphate 0imp 10 ( p & lt ; 0 . 01 ) ara - amp 0tump 0adenosine 0cordycepin 0inosine 0ara - a 0tubercidin 0xylo a 0______________________________________ . sup . a all additions were at 1 × 10 . sup .- 6 m in the infecting solution . . sup . b inhibition of tmv replication was determined 48 hr after infection and calculated as in table 9 , footnote b . table 12______________________________________effect of various concentrations of2 &# 39 ; 5 &# 39 ;- a . sub . 3 , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , and 2 &# 39 ;, 5 &# 39 ;- i . sub . 3on replication in n . glutinosa leavesoligonucleotide concentration inhibitionadded ( m ) (%) ______________________________________no addition -- 02 &# 39 ;, 5 &# 39 ;- a . sub . 3 1 × 10 . sup .- 6 91 ( p & lt ; 0 . 01 ) 1 × 10 . sup .- 7 80 ( p & lt ; 0 . 01 ) 1 × 10 . sup .- 8 75 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- c -- c -- c 1 × 10 . sup .- 6 93 ( p & lt ; 0 . 01 ) 1 × 10 . sup .- 7 84 ( p & lt ; 0 . 01 ) 1 × 10 . sup .- 8 76 ( p & lt ; 0 . 01 ) 2 &# 39 ;, 5 &# 39 ;- i . sub . 3 1 × 10 . sup .- 6 68 ( p & lt ; 0 . 01 ) 1 × 10 . sup .- 7 50 ( p & lt ; 0 . 01 ) 1 × 10 . sup .- 8 36 ( p & lt ; 0 . 01 ) ______________________________________ the morphological transforming efficiencies of ebv - exposed lymphocytes were determined by colony formation in a transformed centers assay ( doetsch , et al , proc . natl . acad . sci . usa 78 , 6699 ( 1981 )). cells were serially diluted into individual wells of a microtiter plate . colonies that developed within 4 weeks were counted with an inverted tissue culture microscope , and the initial colony - forming unit per seeded cell was calculated . transformed colonies were measured 4 - 6 weeks after infection with evb and simultaneous treatment with human leukocyte interferon ( ifn - α ) or 2 &# 39 ;, 5 &# 39 ;- adenylate analog core trimers . 2 &# 39 ;, 5 &# 39 ;- trityl - a 3 , 2 &# 39 ;, 5 &# 39 ;- a -- a - ara - a , 2 &# 39 ;, 5 &# 39 ;- a -- a -- tu , 2 &# 39 ;, 5 &# 39 ;- xylo - a 3 , 2 &# 39 ;, 5 &# 39 ;- xylo - a 4 , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , 2 &# 39 ;, 5 &# 39 ;- a . sub . ( si ) - a . sub . ( si ) - a and 2 &# 39 ;, 5 &# 39 ;- a 3 core inhibited the appearance of transformed colonies . transformation was inhibited in a dose - dependent manner with respect to cell number and interferon or 2 &# 39 ;, 5 &# 39 ;- adenylate analog core concentration . the data are shown in table 13 , demonstrating that marked changes in biological activity may result from subtle structural modifications . table 13______________________________________effects of 2 &# 39 ;, 5 &# 39 ;- adenylate analog cores on ebv - inducedtransformation of adult peripheral blood leukocytes . sup . a2 &# 39 ;, 5 &# 39 ;- adenylate analog transformed centers assay . sup . b ( 300 μm ) 250 25 2 . 5 0 . 25______________________________________experiment 1none 2 / 2 2 / 2 2 / 2 1 / 22 &# 39 ;, 5 &# 39 ;- a -- c -- c 2 / 2 2 / 2 2 / 2 2 / 22 &# 39 ;, 5 &# 39 ;- a -- a -- c 2 / 2 2 / 2 2 / 2 2 / 22 &# 39 ;, 5 &# 39 ;- trityl -- a . sub . 3 1 / 2 0 / 2 0 / 2 0 / 22 &# 39 ;, 5 &# 39 ;- trityl -- c . sub . 3 2 / 2 2 / 2 2 / 2 2 / 22 &# 39 ;, 5 &# 39 ;- a -- a -- ara - a 0 / 2 0 / 2 0 / 2 0 / 22 &# 39 ;, 5 &# 39 ;- a -- a -- tu 0 / 2 0 / 2 0 / 2 0 / 2ifn - α ( 100 units / ml ) 0 / 2 0 / 2 0 / 2 0 / 2experiment 2none 2 / 2 2 / 2 2 / 2 0 / 22 &# 39 ;, 5 &# 39 ;- xylo -- a . sub . 3 2 / 2 0 / 2 0 / 2 0 / 22 &# 39 ;, 5 &# 39 ; xylo -- a . sub . 4 1 / 2 1 / 2 0 / 2 0 / 22 &# 39 ;, 5 &# 39 ;- a -- a -- tu 0 / 2 0 / 2 0 / 2 0 / 22 &# 39 ;, 5 &# 39 ;- c -- c -- c 1 / 2 0 / 2 0 / 2 0 / 22 &# 39 ;, 5 &# 39 ;- a . sub . ( si ) -- a . sub . ( si ) -- a 0 / 2 0 / 2 0 / 2 0 / 2ifn - α ( 100 units / ml ) 0 / 2 0 / 2 0 / 2 0 / 22 &# 39 ;, 5 &# 39 ;- a . sub . 3 2 / 2 1 / 2 0 / 2 0 / 2______________________________________ . sup . a pulsed with compound for 24 hrs , then serially diluted to indicate cell concentrations . . sup . b cell transformants per replicate exposure at cells × 10 . sup . per well ; determined by colony formation in replicate wells of microtiter plates 4 - 6 wk after ebv exposure . inhibition of ascites tumor growth in animals by derivatives of 2 &# 39 ;, 5 &# 39 ;- oligoadenylate core female swiss icr mice ( 25 g , 6 - 8 weeks old ) were injected intraperitoneally with 1 . 5 - 2 × 10 7 ehrlich ascites tumor cells per mouse . animal weight gains were monitored at 2 day intervals . treatments with nucleosides or 2 &# 39 ;, 5 &# 39 ;- adenylate core analogs were accomplished by intraperitoneal injection in 0 . 5 ml phosphate buffered saline 4 days after ascites cell implantation . inhibition of tumor growth is expressed in table 14 as percent of initial weight . table 14______________________________________inhibition of ascites tumor growthby 2 &# 39 ;, 5 &# 39 ;- adenylate core analogs dose percent initial body μmol / 100 g weight after 11 daystreatment body weight % ______________________________________control . sup . a -- 100none . sup . b -- 1392 &# 39 ;, 5 &# 39 ;- c -- c -- c 1 126 2 112 5 98 10 952 &# 39 ;, 5 &# 39 ;- a . sub . 3 5 144 10 1392 &# 39 ;, 5 &# 39 ;- c -- c -- c -- c 2 101 5 982 &# 39 ;, 5 &# 39 ;- a -- a -- c 5 109 10 1082 &# 39 ;, 5 &# 39 ;- a -- c -- c 5 144 10 1383 &# 39 ;, 5 &# 39 ;- a . sub . 3 2 124 5 1112 &# 39 ;, 5 &# 39 ;- i . sub . 3 10 100______________________________________ . sup . a nontumor bearing animal . sup . b tumor bearing animal , no 2 &# 39 ;, 5adenylate core analog treatment at 10 μmole 2 &# 39 ;, 5 &# 39 ;- adenylate core analog per 100 g body weight , 2 &# 39 ;, 5 &# 39 ;- a -- a -- c , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , 2 &# 39 ;, 5 &# 39 ;- c -- c -- c -- c and 2 &# 39 ;, 5 &# 39 ;- i 3 completely inhibited ascites tumor growth in mice for 11 days . after 60 days , there was continued inhibition of tumor growth , with no tumor detectable . in view of the inhibitory activity of 2 &# 39 ;, 5 &# 39 ;- c -- c -- c , 2 &# 39 ;, 5 &# 39 ;- a -- a -- c and 2 &# 39 ;, 5 &# 39 ;- c -- c -- c -- c , it was expected that 2 &# 39 ;, 5 &# 39 ;- a -- a -- c would also be inhibitory . however , there was no inhibition of tumor growth by 2 &# 39 ;, 5 &# 39 ;- a -- c -- c ( see table 14 ). all references herein cited with respect to synthetic or analytical procedures are incorporated herein by reference . the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and , accordingly , reference should be made to the appended claims , rather than to the foregoing specification , as indicating the scope of the invention .
synthetic analogs of 2 &# 39 ;, 5 &# 39 ;- oligoadenylate wherein the aglycon , ribosyl moiety and / or terminal nucleoside have been modified are effective antiviral agents for pharmaceutical and agricultural use . they are particularly useful in inhibiting replication of tobacco mosaic virus . novel synthetic analogs have the following formulae wherein m = 0 , 1 , 2 and 3 and n = 0 , 1 , 2 , 3 or 4 : ## str1 ## the invention described herein was supported by national institutes of health grant gm - 26134 and national science foundation grant pcm - 8111752 .